PMI-001: Phase II data

In a 6-month, double-blind, U.S. Phase II trial in 121 patients, 53.3% of PMI-001 patients had an ACR20 response, the primary endpoint, compared with 21.3% of sulfasalazine-treated patients (p=0.0002)...